130 related articles for article (PubMed ID: 35068389)
1. Post-treatment anti-Mullerian hormone (AMH) levels predict long-term ovarian dysfunction in women with hematological malignancies.
Kongkiatkamon S; Chintabanyat A; Polprasert C; Uaprasert N; Rojnuckarin P
Hematology; 2022 Dec; 27(1):181-186. PubMed ID: 35068389
[TBL] [Abstract][Full Text] [Related]
2. Ovarian reserve after treatment with alkylating agents during childhood.
Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
[TBL] [Abstract][Full Text] [Related]
3. Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review.
Drechsel KCE; Pilon MCF; Stoutjesdijk F; Meivis S; Schoonmade LJ; Wallace WHB; van Dulmen-den Broeder E; Beishuizen A; Kaspers GJL; Broer SL; Veening MA
Hum Reprod Update; 2023 Jul; 29(4):486-517. PubMed ID: 36779325
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
Decanter C; Delepine J; Behal H; Manier S; Bruno B; Barbatti M; Robin C; Labreuche J; Morschhauser F; Pigny P
Hum Reprod; 2021 Sep; 36(10):2743-2752. PubMed ID: 34417822
[TBL] [Abstract][Full Text] [Related]
5. Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay.
Decanter C; Peigne M; Mailliez A; Morschhauser F; Dassonneville A; Dewailly D; Pigny P
Fertil Steril; 2014 Aug; 102(2):483-7. PubMed ID: 24951363
[TBL] [Abstract][Full Text] [Related]
6. Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.
Hamy AS; Porcher R; Cuvier C; Giacchetti S; Schlageter MH; Coussieu C; Gronier H; Feugeas JP; Adoui N; Lacorte JM; Poirot C; Habdous M; Espié M
Reprod Biomed Online; 2014 Nov; 29(5):573-80. PubMed ID: 25246112
[TBL] [Abstract][Full Text] [Related]
7. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood.
van Beek RD; van den Heuvel-Eibrink MM; Laven JS; de Jong FH; Themmen AP; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Pieters R; de Muinck Keizer-Schrama SM
J Clin Endocrinol Metab; 2007 Oct; 92(10):3869-74. PubMed ID: 17726078
[TBL] [Abstract][Full Text] [Related]
8. [Anti-mullerian hormone in young women after chemotherapy and infradiaphragmatic radiotherapy for childhood cancer].
Krawczuk-Rybak M; Leszczyńska E; Wysocka J; Zelazowska-Rutkowska B
Pediatr Endocrinol Diabetes Metab; 2008; 14(2):99-103. PubMed ID: 18721496
[TBL] [Abstract][Full Text] [Related]
9. [Ovarian function in young women after anticancer treatment in childhood].
Krawczuk-Rybak M; Leszczyńska E; Zelazowska-Rutkowska B; Wysocka J
Med Wieku Rozwoj; 2008; 12(4 Pt 2):1028-34. PubMed ID: 19531821
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
Anderson RA; Cameron DA
J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
[TBL] [Abstract][Full Text] [Related]
11. High cytokine expression and reduced ovarian reserve in patients with Hodgkin lymphoma or non-Hodgkin lymphoma.
Paradisi R; Vicenti R; Macciocca M; Seracchioli R; Rossi S; Fabbri R
Fertil Steril; 2016 Oct; 106(5):1176-1182. PubMed ID: 27430206
[TBL] [Abstract][Full Text] [Related]
12. FSHB -211 G>T is a major genetic modulator of reproductive physiology and health in childbearing age women.
Rull K; Grigorova M; Ehrenberg A; Vaas P; Sekavin A; Nõmmemees D; Adler M; Hanson E; Juhanson P; Laan M
Hum Reprod; 2018 May; 33(5):954-966. PubMed ID: 29617818
[TBL] [Abstract][Full Text] [Related]
13. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
Lee DY; Park YH; Lee JE; Choi D
Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
[TBL] [Abstract][Full Text] [Related]
14. Five-year study assessing the clinical utility of anti-Müllerian hormone measurements in reproductive-age women with cancer.
Palinska-Rudzka KE; Ghobara T; Parsons N; Milner J; Lockwood G; Hartshorne GM
Reprod Biomed Online; 2019 Oct; 39(4):712-720. PubMed ID: 31471141
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
[TBL] [Abstract][Full Text] [Related]
16. Anti-Müllerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by ART cycles?
Patrelli TS; Gizzo S; Sianesi N; Levati L; Pezzuto A; Ferrari B; Bacchi Modena A
PLoS One; 2012; 7(9):e44571. PubMed ID: 22984527
[TBL] [Abstract][Full Text] [Related]
17. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of ovarian tissue cryopreservation in female patients with hematological diseases for fertility preservation.
Wang YL; Zhai QJ; Wang ZH; Yang X; Wang JL; Zhu HL
Arch Gynecol Obstet; 2024 Jun; 309(6):2863-2880. PubMed ID: 38575798
[TBL] [Abstract][Full Text] [Related]
19. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.
Wenners A; Grambach J; Koss J; Maass N; Jonat W; Schmutzler A; Mundhenke C
BMC Cancer; 2017 Sep; 17(1):632. PubMed ID: 28877720
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.
Dezellus A; Barriere P; Campone M; Lemanski C; Vanlemmens L; Mignot L; Delozier T; Levy C; Bendavid C; Debled M; Bachelot T; Jouannaud C; Loustalot C; Mouret-Reynier MA; Gallais-Umbert A; Masson D; Freour T
Eur J Cancer; 2017 Jul; 79():72-80. PubMed ID: 28463758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
